Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer

Geng, Peiliang; Chi, Yuling; Yuan, Yuan; Yang, Maoquan; Zhao, Xiaohua; Liu, Zhengchun; Liu, Guangwei; Liu, Yihui; Zhu, Liang; Wang, Shuai

doi:10.3389/fcell.2023.1158539

Cited by 4 publications

(1 citation statement)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chimeric antigen receptor (CAR) T cell therapy and tumor vaccines are emerging strategies for TNBC. CAR-T therapy targeting ROR1 and MUC1 showed promising antitumor activity in preclinical studies ( 79 ). Tumor vaccines, including dendritic cell and peptide vaccines, are under investigation, with ongoing clinical trials assessing their efficacy.…”

Section: Therapeutic Strategies For Tnbcmentioning

confidence: 99%

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

Xiong,

Wu,

2024

Front. Oncol.

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) poses significant challenges in oncology due to its aggressive nature, limited treatment options, and poorer prognosis compared to other breast cancer subtypes. This comprehensive review examines the therapeutic and diagnostic landscape of TNBC, highlighting current strategies, emerging therapies, and future directions. Targeted therapies, including PARP inhibitors, immune checkpoint inhibitors, and EGFR inhibitors, hold promise for personalized treatment approaches. Challenges in identifying novel targets, exploring combination therapies, and developing predictive biomarkers must be addressed to optimize targeted therapy in TNBC. Immunotherapy represents a transformative approach in TNBC treatment, yet challenges in biomarker identification, combination strategies, and overcoming resistance persist. Precision medicine approaches offer opportunities for tailored treatment based on tumor biology, but integration of multi-omics data and clinical implementation present challenges requiring innovative solutions. Despite these challenges, ongoing research efforts and collaborative initiatives offer hope for improving outcomes and advancing treatment strategies in TNBC. By addressing the complexities of TNBC biology and developing effective therapeutic approaches, personalized treatments can be realized, ultimately enhancing the lives of TNBC patients. Continued research, clinical trials, and interdisciplinary collaborations are essential for realizing this vision and making meaningful progress in TNBC management.

show abstract

Section: Therapeutic Strategies For Tnbcmentioning

confidence: 99%

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

Xiong,

Wu,

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective

Filippi,

Urso,

Ferrari

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Introduction Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors. It predominantly affects younger women and is associated with a poor prognosis. This systematic review aims to evaluate the current role of positron emission tomography (PET) in the management of TNBC patients and to identify future research directions. Methods We systematically searched the PubMed, Scopus, and Web of Science databases up to February 2024. A team of five researchers conducted data extraction and analysis. The quality of the selected studies was assessed using a specific evaluation form. Results Twenty-eight studies involving 2870 TNBC patients were included in the review. Key clinical applications of PET in TNBC included predicting pathological complete response (pCR) in patients undergoing neoadjuvant chemotherapy (NAC), assessing the prognostic value of baseline PET, and initial disease staging. Two studies utilized PSMA-ligand agents, while the majority used [18F]FDG-based PET. Significant associations were found between baseline [18F]FDG uptake and molecular biomarkers such as PDL-1, androgen receptor, and Ki67. Baseline [18F]FDG PET led to the upstaging of patients from stage IIB to stage IV, influencing treatment decisions and survival outcomes. In the NAC setting, serial PET scans measuring changes in [18F]FDG uptake, indicated by maximum standardized uptake value (SUVmax), predicted pCR with varying cut-off values correlated with different response rates. Semiquantitative parameters such as metabolic tumor volume (MTV) and PET lung index were prognostic for metastatic disease. Conclusions In TNBC patients, [18F]FDG PET is essential for initial disease staging in both localized and metastatic settings. It is also useful for assessing treatment response to NAC. The ability of PET to correlate metabolic activity with molecular markers and predict treatment outcomes highlights its potential in TNBC management. Further prospective studies are needed to refine these clinical indications and establish its definitive role.

show abstract

Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study

Xiang,

Yang,

Shen

et al. 2024

Heliyon

View full text Add to dashboard Cite

Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer

Cited by 4 publications

References 149 publications

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective

Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study

Contact Info

Product

Resources

About